IL256836B - Methods for treating cancer using apilimod - Google Patents
Methods for treating cancer using apilimodInfo
- Publication number
- IL256836B IL256836B IL256836A IL25683618A IL256836B IL 256836 B IL256836 B IL 256836B IL 256836 A IL256836 A IL 256836A IL 25683618 A IL25683618 A IL 25683618A IL 256836 B IL256836 B IL 256836B
- Authority
- IL
- Israel
- Prior art keywords
- apilimod
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229950002889 apilimod Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562194367P | 2015-07-20 | 2015-07-20 | |
| PCT/US2016/042905 WO2017015262A1 (en) | 2015-07-20 | 2016-07-19 | Methods for treating cancer using apilimod |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL256836A IL256836A (en) | 2018-03-29 |
| IL256836B true IL256836B (en) | 2021-04-29 |
Family
ID=56551023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL256836A IL256836B (en) | 2015-07-20 | 2018-01-10 | Methods for treating cancer using apilimod |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10350213B2 (OSRAM) |
| EP (1) | EP3325014B1 (OSRAM) |
| JP (2) | JP2018525358A (OSRAM) |
| KR (1) | KR20180030630A (OSRAM) |
| CN (1) | CN108025076A (OSRAM) |
| AU (1) | AU2016297555B2 (OSRAM) |
| BR (1) | BR112018000776A2 (OSRAM) |
| CA (1) | CA2991779A1 (OSRAM) |
| IL (1) | IL256836B (OSRAM) |
| MX (1) | MX2018000715A (OSRAM) |
| RU (1) | RU2738934C2 (OSRAM) |
| TW (1) | TWI746449B (OSRAM) |
| WO (1) | WO2017015262A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6855243B2 (ja) | 2014-01-24 | 2021-04-07 | エイアイ・セラピューティクス・インコーポレーテッド | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| ES2741399T3 (es) | 2014-11-07 | 2020-02-10 | Ai Therapeutics Inc | Apilimod para el uso en el tratamiento de cáncer renal |
| WO2016073884A1 (en) * | 2014-11-07 | 2016-05-12 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of colorectal cancer |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| WO2017127661A1 (en) * | 2016-01-21 | 2017-07-27 | Lam Therapeutics, Inc. | Biomarkers for treating cancer with apilimod |
| BR112020004586A2 (pt) | 2017-09-08 | 2020-09-08 | Insignis Therapeutics, Inc. | métodos para uso da dipivefrina |
| EP3755332A1 (en) * | 2018-02-21 | 2020-12-30 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| CN115209952B (zh) | 2020-01-13 | 2025-05-30 | 维基分析有限公司 | 经取代的吡唑并嘧啶及其用途 |
| WO2022094058A1 (en) * | 2020-10-28 | 2022-05-05 | The Regents Of The University Of Michigan | Methods for preventing or treating conditions related to pikfyve activity |
| IL309143A (en) * | 2021-06-11 | 2024-02-01 | Orphai Therapeutics Inc | Stabilized apilimod compositions and uses thereof |
| WO2023108110A2 (en) * | 2021-12-10 | 2023-06-15 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2025175564A1 (en) * | 2024-02-23 | 2025-08-28 | The Regents Of The University Of Michigan | Method for treating autophagy dependent cancer with a pikfyve degrader |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| CU23475A1 (es) * | 2004-07-08 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas |
| TW200630363A (en) | 2004-11-10 | 2006-09-01 | Synta Pharmaceuticals Corp | Process for preparing trisubstituted pyrimidine compounds |
| US7863270B2 (en) | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| WO2006128129A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| RU2350338C2 (ru) * | 2007-05-14 | 2009-03-27 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Способ лечения поверхностного рака мочевого пузыря |
| RU2421217C2 (ru) * | 2009-09-03 | 2011-06-20 | Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) | Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых |
| CN103906756B (zh) * | 2011-09-26 | 2020-03-03 | 加莱拉实验室有限责任公司 | 用于治疗疾病的方法 |
| LT2914296T (lt) * | 2012-11-01 | 2018-09-25 | Infinity Pharmaceuticals, Inc. | Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius |
| US20160022683A1 (en) * | 2013-03-14 | 2016-01-28 | Pharmacyclics Llc | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors |
| WO2014163684A1 (en) * | 2013-04-03 | 2014-10-09 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2015095410A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| EP3082853A2 (en) * | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| JP6855243B2 (ja) * | 2014-01-24 | 2021-04-07 | エイアイ・セラピューティクス・インコーポレーテッド | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
-
2016
- 2016-07-15 TW TW105122406A patent/TWI746449B/zh not_active IP Right Cessation
- 2016-07-19 RU RU2018105923A patent/RU2738934C2/ru active
- 2016-07-19 JP JP2018502669A patent/JP2018525358A/ja active Pending
- 2016-07-19 US US15/213,829 patent/US10350213B2/en not_active Expired - Fee Related
- 2016-07-19 WO PCT/US2016/042905 patent/WO2017015262A1/en not_active Ceased
- 2016-07-19 MX MX2018000715A patent/MX2018000715A/es unknown
- 2016-07-19 AU AU2016297555A patent/AU2016297555B2/en not_active Ceased
- 2016-07-19 CA CA2991779A patent/CA2991779A1/en not_active Abandoned
- 2016-07-19 EP EP16744650.9A patent/EP3325014B1/en active Active
- 2016-07-19 CN CN201680054093.3A patent/CN108025076A/zh active Pending
- 2016-07-19 KR KR1020187004110A patent/KR20180030630A/ko not_active Ceased
- 2016-07-19 BR BR112018000776A patent/BR112018000776A2/pt not_active Application Discontinuation
-
2018
- 2018-01-10 IL IL256836A patent/IL256836B/en active IP Right Grant
-
2021
- 2021-05-19 JP JP2021084241A patent/JP2021121611A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021121611A (ja) | 2021-08-26 |
| AU2016297555B2 (en) | 2021-08-19 |
| TW201717957A (zh) | 2017-06-01 |
| WO2017015262A1 (en) | 2017-01-26 |
| EP3325014B1 (en) | 2021-05-19 |
| EP3325014A1 (en) | 2018-05-30 |
| CA2991779A1 (en) | 2017-01-26 |
| BR112018000776A2 (pt) | 2018-09-04 |
| AU2016297555A1 (en) | 2018-03-01 |
| RU2738934C2 (ru) | 2020-12-18 |
| RU2018105923A3 (OSRAM) | 2019-12-20 |
| MX2018000715A (es) | 2018-06-06 |
| KR20180030630A (ko) | 2018-03-23 |
| CN108025076A (zh) | 2018-05-11 |
| HK1254258A1 (zh) | 2019-07-12 |
| JP2018525358A (ja) | 2018-09-06 |
| RU2018105923A (ru) | 2019-08-20 |
| TWI746449B (zh) | 2021-11-21 |
| US10350213B2 (en) | 2019-07-16 |
| US20170020884A1 (en) | 2017-01-26 |
| IL256836A (en) | 2018-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298497B1 (en) | A method for treating cancer | |
| IL323396A (en) | Cancer treatment methods | |
| IL289947A (en) | A method for treating cancer | |
| SG11201708861VA (en) | Methods for treating cancer | |
| ZA201804227B (en) | Methods of treating cancer | |
| SI3377516T1 (sl) | Sestavek za zdravljenje raka | |
| IL257691A (en) | A method for treating cancer | |
| IL256836B (en) | Methods for treating cancer using apilimod | |
| EP3110509A4 (en) | Method for treating cancer | |
| IL254393A0 (en) | Methods for treating diseases associated with pathological changes in protein | |
| IL255022A0 (en) | Cancer treatment methods | |
| EP3260119A4 (en) | Combination method for treating cancer | |
| IL255079A0 (en) | Methods of treating lung cancer | |
| IL246558A0 (en) | New methods of cancer treatment | |
| IL255018A0 (en) | Cancer treatment methods | |
| IL255016A0 (en) | Cancer treatment methods | |
| SG10201508795XA (en) | Method for treating cancer | |
| HK40098963A (zh) | 治疗癌症的方法 | |
| HK1262818A1 (en) | Methods for treating cancer | |
| HK1262621A1 (en) | Methods for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |